Combined estrogen-progestogen contraceptives and combined estrogen-progestogen menopausal therapy.

Working Group Members1 Garnet L. Anderson, Women’s Health Initiative, Clinical Coordinating Center, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N, M3-A410, PO Box 19024, Seattle, WA 98109, USA Philippe Autier, Unit of Epidemiology, Prevention and Screening, Jules Bordet Institute, Boulevard de Waterloo 125, Brussels 1000, Belgium Valerie Beral, Cancer Epidemiology Unit, University of Oxford, Richard Doll Building, Roosevelt Drive, Headington, Oxford OX3 7LF, United Kingdom (Subgroup Chair, Cancer in Humans) Maarten C. Bosland, Department of Environmental Medicine, New York University School of Medicine, 57 Old Forge Road, Tuxedo, NY 10987, USA (Subgroup Chair, Other Relevant Data) Esteve Fernández, Cancer Prevention & Control Unit, Catalan Institute of Oncology, Avenue Gran Via s/n Km. 2.7, 08907 L’Hospitalet (Barcelona), Spain Sandra Z. Haslam, Breast Cancer & the Environment Research Center, Department of Physiology, Michigan State University, 2201 Biomedical and Physical Sciences Building, East Lansing, MI 48824, USA David G. Kaufman2, Department Pathology & Laboratory Medicine, University of North Carolina at Chapel Hill, 620 Brinkhous-Bullitt Building, CB 7525, Chapel Hill, NC 27599-7525, USA IARC MONOGRAPHS ON THE EVALUATION OF CARCINOGENIC RISKS TO HUMANS: COMBINED ESTROGEN−PROGESTOGEN CONTRACEPTIVES AND COMBINED ESTROGEN− PROGESTOGEN MENOPAUSAL THERAPY